HCV Treatment and Retreatment Study
Treatments studied
Part of Digestive system, Immune system & allergy, Infections clinical trials.
This study tests hepatitis C virus (HCV) treatment using medications called sofosbuvir and velpatasvir, with the goal of curing the infection. If you've been treated before and the virus came back, you may be eligible for retreatment with additional medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 16 years old and able to provide written consent
- Be willing to get tested for HIV, hepatitis C, and hepatitis B
- Be willing to take HCV treatment medications and complete all study visits and activities
- Not have advanced liver damage (cirrhosis with complications)
- Not have previously been treated for your current HCV infection (unless you're in the retreatment group)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a once-daily pill (Epclusa) to treat hepatitis C for people in jail who have never taken HCV medicine before. The goal is to see if starting treatment while incarcerated and continuing after release can cure the infection.
This study tests whether people who come to the emergency department can get tested for hepatitis C and start treatment right away, all in one visit. It aims to make treatment easier and faster for those who test positive.
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
This study compares two ways to treat hepatitis C: getting treatment at a local clinic near you, or the usual care at a central hospital. It aims to see if treatment at local clinics is safe, effective, and more convenient for patients.
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
This trial looks at how two hepatitis C treatments (GLE/PIB or SOF/VEL) interact with other drugs or recreational substances. It may help doctors understand how to better manage treatment for people taking multiple medications.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.